Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
ARV-110, an investigational oral therapy that degrades the androgen receptor, has a favorable safety profile and showed promising anti-tumor activity in ... Read more
Canadian authorities have approved Lynparza (olaparib) as an oral treatment for people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in ... Read more
A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, ... Read more
An investigator-initiated trial soon will evaluate Clinical Laserthermia Systems’ Tranberg Thermal therapy, a focal ablation therapy, for the treatment of prostate ... Read more
Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with ... Read more
Treatment with Corvus Pharmaceuticals‘ ciforadenant (CPI-444), alone or in combination with Tecentriq (atezolizumab), is well tolerated and showed promising anti-tumor activity in ... Read more
The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still ... Read more
A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 — which inhibits the glucocorticoid receptor — ... Read more
